TIZUREST
LIVE

Serial Number

90302471

Owner

EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.

Attorney

Muzamil Huq

Filing Date

Nov 6, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TIZUREST Trademark

Serial Number: 90302471 • Registration: 8155912

TIZUREST is a trademark filed by EVIVE BIOTECHNOLOGY (SHANGHAI) LTD. on November 6, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

EVIVE BIOTECHNOLOGY (SHANGHAI) LTD. (5 trademarks)

China (Shanghai) Pilot Free Trade Zone
Shanghai 201207 , CN

Entity Type: 03

Generon (Shanghai) Corporation Ltd. (7 trademarks)

Suite 307, 1011 Ha Lei Road
Shanghai 201204 , CN

Entity Type: 03

Trademark Details

Filing Date

November 6, 2020

Registration Date

March 3, 2026

Published for Opposition

December 13, 2022

Goods & Services

Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; human medicines for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; biochemical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medicinal capsules for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical biological preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical ointments, namely, medicated ointments for treating or preventing inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical diagnostic preparations

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 3, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 3, 2026 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Feb 9, 2026 DP1B
NOTICE OF ALLOWANCE CANCELLED
Feb 6, 2026 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Feb 6, 2026 D1BR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 23, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 22, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 22, 2025 AITU
SOU EXTENSION 5 FILED
Aug 4, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 1, 2025 EXRA
SOU EXTENSION 4 GRANTED
Feb 1, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 31, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 31, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 24, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 23, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 23, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 22, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 7, 2024 EXRA
SOU EXTENSION 2 GRANTED
Feb 5, 2024 EX2G
SOU EXTENSION 2 FILED
Feb 5, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 5, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 22, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 22, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 22, 2024 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 3, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 3, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 3, 2024 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2023 EXRA
SOU EXTENSION 1 GRANTED
Aug 7, 2023 EX1G
SOU EXTENSION 1 FILED
Aug 7, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 7, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 7, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 13, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 13, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 23, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 10, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 10, 2022 CRFA
ASSIGNED TO LIE
Nov 8, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 26, 2022 ERSI
ASSIGNED TO EXAMINER
May 31, 2022 DOCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 20, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 20, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 20, 2022 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 4, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 4, 2021 GNSL
SUSPENSION LETTER WRITTEN
Oct 4, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 30, 2021 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 16, 2021 ASGN
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 16, 2021 GPRN
PRIORITY ACTION E-MAILED
Apr 16, 2021 GPRA
PRIORITY ACTION WRITTEN
Apr 16, 2021 CPRA
ASSIGNED TO EXAMINER
Apr 14, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 6, 2021 NWOS
NEW APPLICATION ENTERED
Nov 10, 2020 NWAP